Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

fiercepharma.com

FiercePharma

Get the latest updates from FiercePharma directly as they happen.

Follow now 363 followers

Latest posts

Last updated about 12 hours ago

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

about 12 hours ago

A rival bidder has emerged to acquire struggling gene therapy specialist bluebird...

Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target

about 17 hours ago

After much delay, Novartis has finally won a key FDA go-ahead for...

Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market

about 17 hours ago

Over the last three years, the FDA has approved six new drugs...

Pharma Marketing in 2025: A Conversation with Fierce Pharma

about 17 hours ago

Pharma Marketing in 2025: A Conversation with Fierce Pharma

Eli Lilly's Alzheimer's contender Kisunla gets thumbs down from EU regulators over safety concerns

about 20 hours ago

After failing to pass muster with England’s drug reimbursement watchdog earlier this...

Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M

about 21 hours ago

Gilead CEO Daniel O’Day saw another rise in his pay in 2024...

AstraZeneca, Sanofi, Lilly, Pfizer CEOs meet with Xi Jinping amid US-China trade tensions

about 21 hours ago

As U.S. President Donald Trump threatens a new round of tariffs as...

Senate investigation claims Pfizer shifted profits offshore in what could be pharma's 'largest tax-dodging scheme'

about 21 hours ago

Four years into a Congressional probe of Big Pharma’s potential abuse of...

Moderna brand chief Kate Cronin leaves for 'next chapter'

about 21 hours ago

Kate Cronin, who took the marketing reins at Moderna in 2021 as...

Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians

about 22 hours ago

Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their...

Fierce Pharma Asia—Novo's triple G obesity bet; Merck's latest China deal; Hengrui, Elevar's 2nd FDA snub

about 23 hours ago

Novo Nordisk snagged an obesity asset from China's United Laboratories for up...

Manufacturing issues trip up Milestone's long-awaited FDA landmark

about 23 hours ago

The FDA has rejected Milestone Pharmaceuticals’ application for approval of Cardamyst (etripamil)...